264 related articles for article (PubMed ID: 21851388)
21. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Eriksson BI; Quinlan DJ; Eikelboom JW
Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
[TBL] [Abstract][Full Text] [Related]
22. Improving prevention and treatment of venous thromboembolism: clinical trial results.
Mahan C; Spyropoulos AC
J Med Econ; 2012; 15(4):611-22. PubMed ID: 22372589
[TBL] [Abstract][Full Text] [Related]
23. Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.
Friedman RJ; Sengupta N; Lees M
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):299-306. PubMed ID: 21671699
[TBL] [Abstract][Full Text] [Related]
24. New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Fisher WD
Am J Manag Care; 2011 Feb; 17(1 Suppl):S15-21. PubMed ID: 21517651
[TBL] [Abstract][Full Text] [Related]
25. New oral anticoagulants: should they replace heparins and warfarin?
Tsiara S; Pappas K; Boutsis D; Laffan M
Hellenic J Cardiol; 2011; 52(1):52-67. PubMed ID: 21292607
[No Abstract] [Full Text] [Related]
26. New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
den Exter PL; Kooiman J; van der Hulle T; Huisman MV
Best Pract Res Clin Haematol; 2013 Jun; 26(2):163-9. PubMed ID: 23953904
[TBL] [Abstract][Full Text] [Related]
27. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
[TBL] [Abstract][Full Text] [Related]
28. [New oral anticoagulants: prospects].
Fiessinger JN
Rev Prat; 2010 May; 60(5):613-6. PubMed ID: 20564841
[TBL] [Abstract][Full Text] [Related]
29. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
30. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Tripodi A; Palareti G
J Intern Med; 2012 Jun; 271(6):554-65. PubMed ID: 22443239
[TBL] [Abstract][Full Text] [Related]
31. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
Drug Ther Bull; 2009 Oct; 47(10):116-20. PubMed ID: 19809086
[TBL] [Abstract][Full Text] [Related]
33. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
34. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Dobesh PP; Fanikos J
Drugs; 2014 Nov; 74(17):2015-32. PubMed ID: 25300410
[TBL] [Abstract][Full Text] [Related]
35. New oral therapies for the prevention and treatment of venous thromboembolism.
Hellwig T; Gulseth M
Am J Health Syst Pharm; 2013 Jan; 70(2):113-25. PubMed ID: 23292264
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
Schellong S
Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
[TBL] [Abstract][Full Text] [Related]
37. New anticoagulants for treatment of venous thromboembolism.
Gross PL; Weitz JI
Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):380-6. PubMed ID: 18296593
[TBL] [Abstract][Full Text] [Related]
38. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.
Harder S; Graff J
Eur J Clin Pharmacol; 2013 Sep; 69(9):1617-33. PubMed ID: 23619611
[TBL] [Abstract][Full Text] [Related]
39. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
[No Abstract] [Full Text] [Related]
40. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Sattari M; Lowenthal DT
Am J Ther; 2011 Jul; 18(4):332-8. PubMed ID: 20535013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
